Intra-arterial approaches to stem cell therapy for ischemic stroke

Vikram Jadhav, Pallab Bhattacharya, Dileep R Yavagal

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Stroke remains the leading cause of disability and among the top five causes of death around the world. While recanalization therapies, first approved about two decades ago for ischemic stroke, have changed the nihilistic approach that prevailed in the past, their impact remains small. Hence, there is a critical need to translate novel stroke therapies to reduce the burden of ischemic stroke. There is a strong biologic rationale for cell-based therapy with a variety of stem cells in ischemic stroke, given that the brain’s repair process after stroke is driven by endogenous stem cells. Over the last 15 years, numerous preclinical studies of cell-based therapy for ischemic stroke show consistent promise of safety and efficacy. While these studies utilize a variety of cells and different routes of cell administration, the intra-arterial route of cell delivery has several attractive clinical attributes including minimally invasive and targeted delivery of cells to area of brain injury. This route of delivery of cells has been the focus of our laboratory and here we review the preclinical data and the recent rise in published early clinical trials of cell-based therapy in ischemic stroke. These clinical trial data in their sum total suggest robust safety of this approach and set the stage for the next phase of clinical trials to establish its clinical efficacy in this devastating disease.

Original languageEnglish (US)
Title of host publicationCell Therapy for Brain Injury
PublisherSpringer International Publishing
Pages65-89
Number of pages25
ISBN (Print)9783319150635, 9783319150628
DOIs
StatePublished - Jan 1 2015

Fingerprint

Cell- and Tissue-Based Therapy
Stem cells
Brain
Stem Cells
Stroke
Repair
Clinical Trials
Safety
Brain Injuries
Cause of Death
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Neuroscience(all)

Cite this

Jadhav, V., Bhattacharya, P., & Yavagal, D. R. (2015). Intra-arterial approaches to stem cell therapy for ischemic stroke. In Cell Therapy for Brain Injury (pp. 65-89). Springer International Publishing. https://doi.org/10.1007/978-3-319-15063-5_6

Intra-arterial approaches to stem cell therapy for ischemic stroke. / Jadhav, Vikram; Bhattacharya, Pallab; Yavagal, Dileep R.

Cell Therapy for Brain Injury. Springer International Publishing, 2015. p. 65-89.

Research output: Chapter in Book/Report/Conference proceedingChapter

Jadhav, V, Bhattacharya, P & Yavagal, DR 2015, Intra-arterial approaches to stem cell therapy for ischemic stroke. in Cell Therapy for Brain Injury. Springer International Publishing, pp. 65-89. https://doi.org/10.1007/978-3-319-15063-5_6
Jadhav V, Bhattacharya P, Yavagal DR. Intra-arterial approaches to stem cell therapy for ischemic stroke. In Cell Therapy for Brain Injury. Springer International Publishing. 2015. p. 65-89 https://doi.org/10.1007/978-3-319-15063-5_6
Jadhav, Vikram ; Bhattacharya, Pallab ; Yavagal, Dileep R. / Intra-arterial approaches to stem cell therapy for ischemic stroke. Cell Therapy for Brain Injury. Springer International Publishing, 2015. pp. 65-89
@inbook{c6629e01e19247b9b2f13f01d5fb5537,
title = "Intra-arterial approaches to stem cell therapy for ischemic stroke",
abstract = "Stroke remains the leading cause of disability and among the top five causes of death around the world. While recanalization therapies, first approved about two decades ago for ischemic stroke, have changed the nihilistic approach that prevailed in the past, their impact remains small. Hence, there is a critical need to translate novel stroke therapies to reduce the burden of ischemic stroke. There is a strong biologic rationale for cell-based therapy with a variety of stem cells in ischemic stroke, given that the brain’s repair process after stroke is driven by endogenous stem cells. Over the last 15 years, numerous preclinical studies of cell-based therapy for ischemic stroke show consistent promise of safety and efficacy. While these studies utilize a variety of cells and different routes of cell administration, the intra-arterial route of cell delivery has several attractive clinical attributes including minimally invasive and targeted delivery of cells to area of brain injury. This route of delivery of cells has been the focus of our laboratory and here we review the preclinical data and the recent rise in published early clinical trials of cell-based therapy in ischemic stroke. These clinical trial data in their sum total suggest robust safety of this approach and set the stage for the next phase of clinical trials to establish its clinical efficacy in this devastating disease.",
author = "Vikram Jadhav and Pallab Bhattacharya and Yavagal, {Dileep R}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-319-15063-5_6",
language = "English (US)",
isbn = "9783319150635",
pages = "65--89",
booktitle = "Cell Therapy for Brain Injury",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Intra-arterial approaches to stem cell therapy for ischemic stroke

AU - Jadhav, Vikram

AU - Bhattacharya, Pallab

AU - Yavagal, Dileep R

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Stroke remains the leading cause of disability and among the top five causes of death around the world. While recanalization therapies, first approved about two decades ago for ischemic stroke, have changed the nihilistic approach that prevailed in the past, their impact remains small. Hence, there is a critical need to translate novel stroke therapies to reduce the burden of ischemic stroke. There is a strong biologic rationale for cell-based therapy with a variety of stem cells in ischemic stroke, given that the brain’s repair process after stroke is driven by endogenous stem cells. Over the last 15 years, numerous preclinical studies of cell-based therapy for ischemic stroke show consistent promise of safety and efficacy. While these studies utilize a variety of cells and different routes of cell administration, the intra-arterial route of cell delivery has several attractive clinical attributes including minimally invasive and targeted delivery of cells to area of brain injury. This route of delivery of cells has been the focus of our laboratory and here we review the preclinical data and the recent rise in published early clinical trials of cell-based therapy in ischemic stroke. These clinical trial data in their sum total suggest robust safety of this approach and set the stage for the next phase of clinical trials to establish its clinical efficacy in this devastating disease.

AB - Stroke remains the leading cause of disability and among the top five causes of death around the world. While recanalization therapies, first approved about two decades ago for ischemic stroke, have changed the nihilistic approach that prevailed in the past, their impact remains small. Hence, there is a critical need to translate novel stroke therapies to reduce the burden of ischemic stroke. There is a strong biologic rationale for cell-based therapy with a variety of stem cells in ischemic stroke, given that the brain’s repair process after stroke is driven by endogenous stem cells. Over the last 15 years, numerous preclinical studies of cell-based therapy for ischemic stroke show consistent promise of safety and efficacy. While these studies utilize a variety of cells and different routes of cell administration, the intra-arterial route of cell delivery has several attractive clinical attributes including minimally invasive and targeted delivery of cells to area of brain injury. This route of delivery of cells has been the focus of our laboratory and here we review the preclinical data and the recent rise in published early clinical trials of cell-based therapy in ischemic stroke. These clinical trial data in their sum total suggest robust safety of this approach and set the stage for the next phase of clinical trials to establish its clinical efficacy in this devastating disease.

UR - http://www.scopus.com/inward/record.url?scp=84943389466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943389466&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-15063-5_6

DO - 10.1007/978-3-319-15063-5_6

M3 - Chapter

SN - 9783319150635

SN - 9783319150628

SP - 65

EP - 89

BT - Cell Therapy for Brain Injury

PB - Springer International Publishing

ER -